Compare Cipla with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ALEMBIC LTD - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ALEMBIC LTD CIPLA/
ALEMBIC LTD
 
P/E (TTM) x 23.6 76.0 31.1% View Chart
P/BV x 2.6 2.7 95.9% View Chart
Dividend Yield % 0.6 0.4 164.4%  

Financials

 CIPLA   ALEMBIC LTD
EQUITY SHARE DATA
    CIPLA
Mar-19
ALEMBIC LTD
Mar-18
CIPLA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs67872 941.7%   
Low Rs48434 1,427.1%   
Sales per share (Unadj.) Rs198.24.7 4,217.0%  
Earnings per share (Unadj.) Rs18.56.1 303.5%  
Cash flow per share (Unadj.) Rs35.06.2 560.2%  
Dividends per share (Unadj.) Rs3.000.20 1,500.0%  
Dividend yield (eoy) %0.50.4 136.7%  
Book value per share (Unadj.) Rs186.340.7 458.2%  
Shares outstanding (eoy) m805.70267.03 301.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.911.3 26.0%   
Avg P/E ratio x31.48.7 361.5%  
P/CF ratio (eoy) x16.68.5 195.8%  
Price / Book Value ratio x3.11.3 239.4%  
Dividend payout %16.23.3 494.3%   
Avg Mkt Cap Rs m468,03114,139 3,310.2%   
No. of employees `00022.6NA-   
Total wages/salary Rs m28,565207 13,773.0%   
Avg. sales/employee Rs Th7,053.1NM-  
Avg. wages/employee Rs Th1,261.5NM-  
Avg. net profit/employee Rs Th659.1NM-  
INCOME DATA
Net Sales Rs m159,7101,255 12,723.8%  
Other income Rs m4,766370 1,287.3%   
Total revenues Rs m164,4751,625 10,119.1%   
Gross profit Rs m30,973111 27,878.6%  
Depreciation Rs m13,26338 35,087.6%   
Interest Rs m1,6842 99,076.5%   
Profit before tax Rs m20,791442 4,706.1%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,69524 23,780.0%   
Profit after tax Rs m14,9241,630 915.7%  
Gross profit margin %19.48.9 219.1%  
Effective tax rate %27.45.4 505.3%   
Net profit margin %9.3129.8 7.2%  
BALANCE SHEET DATA
Current assets Rs m124,2661,867 6,655.6%   
Current liabilities Rs m37,715591 6,379.4%   
Net working cap to sales %54.2101.6 53.3%  
Current ratio x3.33.2 104.3%  
Inventory Days Days9194 96.1%  
Debtors Days Days9574 129.0%  
Net fixed assets Rs m105,1901,791 5,873.6%   
Share capital Rs m1,611534 301.7%   
"Free" reserves Rs m148,51110,324 1,438.6%   
Net worth Rs m150,12310,858 1,382.6%   
Long term debt Rs m38,30141 92,962.9%   
Total assets Rs m239,63311,591 2,067.5%  
Interest coverage x13.3260.9 5.1%   
Debt to equity ratio x0.30 6,723.6%  
Sales to assets ratio x0.70.1 615.4%   
Return on assets %6.914.1 49.2%  
Return on equity %9.915.0 66.2%  
Return on capital %11.815.2 77.9%  
Exports to sales %34.71.5 2,245.1%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs m55,41919 285,664.4%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m57,41019 295,925.3%   
Fx outflow Rs m19,041264 7,217.5%   
Net fx Rs m38,368-244 -15,697.7%   
CASH FLOW
From Operations Rs m16,911236 7,171.9%  
From Investments Rs m-16,687-224 7,449.5%  
From Financial Activity Rs m-3,487-27 13,109.8%  
Net Cashflow Rs m-3,451-15 23,318.2%  

Share Holding

Indian Promoters % 16.0 64.0 25.0%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 0.2 6,100.0%  
FIIs % 23.7 9.7 244.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 26.1 100.4%  
Shareholders   161,166 54,701 294.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 20, 2019 (Close)

TRACK CIPLA

CIPLA - ELDER PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS